Ajanta Pharma, a Rs.1,700 crore plus pharma major from Mumbai, has received US FDA approval for omeprazole and sodium bicarbonate powder for oral suspension. It is a bioequivalent generic version of Zegerid powder for oral suspension and the company will be launching the product soon in 2 strengths 20mg/1680 mg and 40mg/1680 mg powder sachets.

This approval is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 ANDAs, of which it has final approvals for 12 ANDAs; tentative approvals for 1 ANDA and 13 ANDAs are under review with US FDA.

Ajanta scrip has taken jump and reached at its yearly highest level today in the morning session on BSE to Rs.1776.75.